 Since most of the patients with CCA are treated in large centers a chemotherapy protocol with limited numbers of intravenous infusions appears to be very comfortable for patients with CCA. A further argument for the investigation of CisplatinGemcitabinePanitumumab in a randomized phase II study is the fact that the 3-week interval of the CisGem protocol fits very well into the 3-week interval of the Panitumumab schedule. 